Search
treprostinil (Tyvaso, Unipros, Remodulin, Senicopac, Orenitram)
Indication:
- treatment of pulmonary arterial hypertension, including when due to interstitial lung disease [2]
Dosage:
- for inhalation, 1-3 inhalations QID
- administer undiluted, as supplied
- a single inhalation of Tyvaso delivers ~6 mcg of treprostinil
Sterile solution for oral inhalation:
- 2.9 mL ampule containing 1.74 mg treprostinil (0.6 mg/mL)
Pharmacokinetics:
- metabolized by cyt P450 2C8
Adverse effects:
- most common adverse reactions (10%)
- cough, headache, nausea dizziness, flushing, throat irritation, pharyngolaryngeal pain, diarrhea
Drug interactions:
- concomitant diuretics, antihypertensives or other vasodilators may increase the risk of hypotension
Mechanism of action:
- prostacyclin vasodilator
Interactions
drug adverse effects of antihypertensive agents
General
prostaglandin I (prostacyclin, epoprostenol {Flolan})
vasodilator agent
Database Correlations
PUBCHEM correlations
References
- Prescriber's Letter 17(2): 2010
New Drugs Approved by the FDA in 2009
Detail-Document#: 260213
(subscription needed) http://www.prescribersletter.com
- Waxman A, Restrepo-Jaramillo R, Thenappan T et al
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial
Lung Disease.
N Engl J Med 2021. Jan 13,
PMID: 33440084
https://www.nejm.org/doi/full/10.1056/NEJMoa2008470
- Taichman DB
Optimism for Interstitial Lung Disease-Associated Pulmonary Hypertension?
N Engl J Med 2021. Jan 13,
PMID: 33440083
https://www.nejm.org/doi/full/10.1056/NEJMe2033181